Home > Medical News > Medical World News > The Safety of 1-(10,11-Dihydro-5H-dibenzo[a,d]cyclohepten-5-yl)piperazine

The Safety of 1-(10,11-Dihydro-5H-dibenzo[a,d]cyclohepten-5-yl)piperazine

  • Last Update: 2023-05-09
  • Source: Internet
  • Author: User
Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

1-(10,11-Dihydro-5H-dibenzo[a,d]cyclohepten-5-yl)piperazine, commonly referred to as Benzoylphenylpiperazine (BPP), is a synthetic chemical compound that has been widely used in various industrial applications.
However, concerns about its safety have been raised due to its potential toxicity.
This article explores the safety of BPP in the chemical industry.


BPP is primarily used as a catalyst in the production of plastics and other synthetic materials.
It is also used as a solvent in the production of coatings, inks, and other industrial chemicals.
Despite its widespread use, limited research has been conducted on its safety, and what research has been conducted has yielded conflicting results.


One of the main concerns surrounding BPP is its potential toxicity.
Studies have shown that BPP can cause skin irritation, respiratory problems, and other health issues in laboratory animals when ingested or inhaled.
Additionally, some studies have suggested that BPP may be carcinogenic, which means it has the potential to cause cancer in humans.


However, other studies have found no evidence of BPP's carcinogenic potential or noted that the potential risks associated with its use are small.
The conflicting results have led to confusion and uncertainty about the safety of BPP, which has raised concerns among regulatory agencies and environmental groups.


Despite the conflicting results, several countries have classified BPP as a potential carcinogen, which means that exposure to the chemical should be limited as much as possible.
The European Union has classified BPP as a Category 2 carcinogen, which means that it is possibly carcinogenic to humans.
Similarly, the United States Environmental Protection Agency (EPA) has classified BPP as a Group B2, probable human carcinogen.


The safety concerns surrounding BPP have led to increased regulation of its use in various countries.
In the United States, the EPA has implemented regulations on the use of BPP in certain industrial processes, including its use as a solvent in the production of certain chemicals.
Additionally, the Occupational Safety and Health Administration (OSHA) has established limits on the amount of BPP that workers can be exposed to in the workplace.


In Europe, the use of BPP is also subject to strict regulations, including the REACH regulation, which requires manufacturers of chemicals to provide evidence of their safety before they can be used in products.
The European Chemicals Agency (ECHA) has also classified BPP as a Category 2 carcinogen, which means that it can only be used in industrial processes if the risks are properly controlled.


In conclusion, the safety of 1-(10,11-Dihydro-5H-dibenzo[a,d]cyclohepten-5-yl)piperazine is a subject of ongoing debate and concern.
While some studies have suggested that it may be carcinogenic, others have found no evidence of its potential risks.
Regulatory agencies in various countries have responded to the uncertainty by implementing regulations on its use, which have led to various restrictions on its use in industrial processes.
It is important for manufacturers of BPP to be transparent about its potential risks and to take appropriate measures to minimize exposure to the chemical.


This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

Contact Us

The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.